CN105980377B - 作为egfr-t790m激酶抑制剂的取代的嘧啶类化合物 - Google Patents

作为egfr-t790m激酶抑制剂的取代的嘧啶类化合物 Download PDF

Info

Publication number
CN105980377B
CN105980377B CN201580007044.XA CN201580007044A CN105980377B CN 105980377 B CN105980377 B CN 105980377B CN 201580007044 A CN201580007044 A CN 201580007044A CN 105980377 B CN105980377 B CN 105980377B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
compounds
acceptable salt
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580007044.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105980377A (zh
Inventor
张大为
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Medolution Ltd
Original Assignee
Jiangsu Medolution Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Medolution Ltd filed Critical Jiangsu Medolution Ltd
Publication of CN105980377A publication Critical patent/CN105980377A/zh
Application granted granted Critical
Publication of CN105980377B publication Critical patent/CN105980377B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580007044.XA 2014-02-04 2015-02-03 作为egfr-t790m激酶抑制剂的取代的嘧啶类化合物 Active CN105980377B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461965584P 2014-02-04 2014-02-04
US61/965,584 2014-02-04
PCT/CN2015/072179 WO2015117547A1 (en) 2014-02-04 2015-02-03 Substituted pyrimidines useful as egfr-t790m kinase inhibitors

Publications (2)

Publication Number Publication Date
CN105980377A CN105980377A (zh) 2016-09-28
CN105980377B true CN105980377B (zh) 2018-07-03

Family

ID=53777338

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580007044.XA Active CN105980377B (zh) 2014-02-04 2015-02-03 作为egfr-t790m激酶抑制剂的取代的嘧啶类化合物

Country Status (8)

Country Link
US (1) US10167264B2 (https=)
EP (1) EP3102571B1 (https=)
JP (1) JP6257787B2 (https=)
CN (1) CN105980377B (https=)
DK (1) DK3102571T3 (https=)
ES (1) ES2667847T3 (https=)
NO (1) NO2718543T3 (https=)
WO (1) WO2015117547A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106554347B (zh) * 2015-09-25 2020-10-30 浙江博生医药有限公司 Egfr激酶抑制剂及其制备方法和应用
CN106554318A (zh) * 2015-09-25 2017-04-05 正大天晴药业集团股份有限公司 氘代二苯基氨基嘧啶化合物
CN105461640B (zh) * 2015-12-02 2017-11-21 芷威（上海）化学科技有限公司 一种酪氨酸激酶抑制剂的制备方法
CN106146406A (zh) * 2016-02-23 2016-11-23 深圳市塔吉瑞生物医药有限公司 一种取代的二氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN107344925B (zh) * 2016-05-04 2022-11-11 正大天晴药业集团股份有限公司 氘代二苯基氨基-三氟甲基嘧啶化合物
CN107088196A (zh) * 2017-02-27 2017-08-25 王涛 一种治疗骨质疏松症的药物组合物
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CA3139969A1 (en) * 2019-06-20 2020-12-24 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of src tyrosine kinase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103269704A (zh) * 2010-11-01 2013-08-28 西建阿维拉米斯研究公司 杂环化合物和其用途
WO2013138495A1 (en) * 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
WO2013138502A1 (en) * 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
CA2861010A1 (en) * 2012-01-13 2013-07-18 Xiao Xu Heterocyclic compounds and uses as anticancer agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103269704A (zh) * 2010-11-01 2013-08-28 西建阿维拉米斯研究公司 杂环化合物和其用途
WO2013138495A1 (en) * 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
WO2013138502A1 (en) * 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor

Also Published As

Publication number Publication date
DK3102571T3 (en) 2018-05-07
JP6257787B2 (ja) 2018-01-10
ES2667847T3 (es) 2018-05-14
WO2015117547A1 (en) 2015-08-13
US10167264B2 (en) 2019-01-01
CN105980377A (zh) 2016-09-28
EP3102571A4 (en) 2016-12-14
JP2017505319A (ja) 2017-02-16
EP3102571B1 (en) 2018-04-04
US20170008856A1 (en) 2017-01-12
NO2718543T3 (https=) 2018-01-06
EP3102571A1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
CN105980377B (zh) 作为egfr-t790m激酶抑制剂的取代的嘧啶类化合物
CN105461695B (zh) 嘧啶或三嗪衍生物及其制备方法和用途
CN112608318B (zh) 一种作为蛋白质激酶抑制剂的化合物及其用途
TWI418554B (zh) 結晶形（ｒ）－（ｅ）－２－（４－（２－（５－（１－（３，５－二氯吡啶－４－基）乙氧基）－１ｈ－吲唑－３－基）乙烯基）－１ｈ－吡唑－１－基）乙醇
CN105408334B (zh) 作为激酶抑制剂的取代的吡唑并嘧啶类化合物
CN100412066C (zh) 用作蛋白激酶抑制剂的化合物和组合物
JP2009511558A (ja) 癌の処置のためのピリミジン誘導体
KR20170031241A (ko) 시클린-의존성 키나제 (cdk) 억제제로서의 2-h-인다졸 유도체 및 그의 치료적 용도
CN111362967A (zh) 苯并氧杂二氮杂十四碳烯衍生物及其用途
JP2011207909A (ja) フラザノベンゾイミダゾール
JP2021512161A (ja) Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ−インダゾール誘導体およびその治療上の使用
CN111542522B (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
TW201934546A (zh) 嘧啶類化合物、其製備方法及其醫藥用途
KR20120103553A (ko) 신규 １,２,３,４-테트라히드로-피리미도（１,２-ａ）피리미딘-６-온 유도체, 그의 제조법 및 그의 제약 용도
TW202214603A (zh) 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用
JP6609308B2 (ja) キナーゼ阻害剤としての置換マクロサイクル
CN109641909B (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN104829613B (zh) 二芳基取代的吡唑并环类衍生物、其制备方法及其在医药领域的应用
WO2020052489A1 (zh) 一种6-氨基-1h-吡唑并[3,4-d]嘧啶类jak激酶抑制剂的制备与应用
CN105050602B (zh) 作为pi3激酶抑制剂的吡啶化合物
WO2014071824A1 (zh) 4-氨基喹唑啉杂环化合物及其用途
TW201934547A (zh) 一種嘧啶類化合物、其製備方法及其醫藥用途
CN118359627A (zh) 具有四环并环结构的mta协同性prmt5抑制剂化合物
CN120081824A (zh) 一种Betti碱衍生物及其合成方法和应用
CN118221696A (zh) 含有n-甲基哌嗪结构的嘧啶杂环类化合物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PP01 Preservation of patent right
PP01 Preservation of patent right

Effective date of registration: 20190613

Granted publication date: 20180703

PD01 Discharge of preservation of patent
PD01 Discharge of preservation of patent

Date of cancellation: 20190816

Granted publication date: 20180703